ASMB at a glance
Assembly Biosciences Inc (ASMB, SEC CIK 1426800) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as November 3, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Assembly Biosciences Inc (ASMB) reported revenue of $72.3 million (up 153.5% from FY2024) and a net loss of $6.1 million. Diluted EPS was -$0.55.
- As of September 30, 2026, 22 institutional investment managers tracked by SignalX reported holding Assembly Biosciences Inc (ASMB) shares worth $226.2 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by White Nicole S on November 2, 2026 of 29 shares at $20.35 per share.
- In the last 90 days, ASMB insiders reported 0 open-market purchases ($0) and 8 open-market sales ($238K) on Form 4, a net sale of $238K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $72.3M
- +153.5% vs prior year
- Insiders · 90 days
- 0 buys · 8 sells
- Net −$238K
- 13F holders
- 22 funds
- $226.2M · +0 vs prior quarter
- Latest 8-K
- Nov 12, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Q3 collaboration revenue $3.0M, down 73% YoY from $10.8M
- Q3 R&D expenses $20.2M vs $16.6M YoY, driven by 6250 trial startups
- Best program momentum: 6250 Phase 2 HDV dosing initiated; CLD Phase 2 planned for Q1 2027
- Operating cash used $54.7M through September, cash and securities $314.3M at September 30
- Outlook: funds expected to support operations into 2029, including Gilead’s $75.0M extension payment
Risk Factors
- Newly added regulatory risk: FDA workforce downsizing and eliminated positions could delay inspections, reviews, guidance, and approvals
- Most materially updated collaboration risk: Gilead declined 4334 licensing in March 2026, potentially slowing development and commercialization
- Data privacy compliance risk: EU and UK GDPR violations can trigger fines up to €20 million, £17.5 million, or 4% of global revenue
- Operational risk: Foreign CROs and suppliers face China scrutiny, tariffs, geopolitical disruptions, and supply-chain interruptions
- Financial risk: Gilead owned approximately 24.4% of common stock and may increase ownership to 35%
AI summary of the ASMB 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced for the quarter ended September 30, 2026
- Detailed results and management commentary available in Exhibit 99.1, relevant for assessing cash runway and clinical funding ability
Item EX-99.1: Item EX-99.1
- Cash, equivalents and marketable securities $314.3M plus $75M Gilead fee, extending projected runway into 2029
- 40% U.S. HSV program cost and profit share increases future commercial upside and development spending exposure
Item EX-99.1: Item EX-99.1
- Q2 revenue $13.4M, up from $9.6M, including a $5.1M cumulative catch-up from Gilead collaboration estimates
- Net loss narrowed to $3.9M, or $0.20 per share, from $10.2M, or $1.33, helped by collaboration revenue and interest income
Item 2.02: Results of Operations and Financial Condition
- Assembly Biosciences announced financial results for the quarter ended June 30, 2026
- Exhibit 99.1 contains the substantive financial results and management commentary
Item 2.02: Results of Operations and Financial Condition
- Press release covers Assembly Biosciences’ quarter ended June 30, 2026
- Exhibit 99.1 contains the company’s financial results and management commentary
Item EX-99.1: Item EX-99.1
- Q2 revenue $13.4M, up from $9.6M, including a $5.1M cumulative catch-up adjustment tied to Gilead activities
- Net loss narrowed to $3.9M, or $0.20 per share, from $10.2M, or $1.33, supported by higher revenue and interest income
AI summaries of ASMB 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ASMB
Don't miss the next ASMB filing
- Alerts as it files. A push when ASMB files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ASMB, by share count.
- Ask anything. An AI agent that reads every ASMB filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| White Nicole S | Sell | Nov 2, 2026 | 29 | $20.35 |
| Bjorkquist Jeanette M | Sell | Nov 2, 2026 | 9 | $20.35 |
| Okazaki Jason A | Sell | Nov 2, 2026 | 69 | $20.35 |
| White Nicole S | Sell | Nov 2, 2026 | 2,564 | $19.61 |
| Gaggar Anuj | Sell | Nov 2, 2026 | 29 | $20.35 |
| Gaggar Anuj | Sell | Nov 2, 2026 | 2,564 | $19.61 |
| Bjorkquist Jeanette M | Sell | Nov 2, 2026 | 718 | $19.61 |
| Okazaki Jason A | Sell | Nov 2, 2026 | 6,133 | $19.61 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $28.5M | $72.3M |
| Operating Income | - | -$45.4M | -$12.1M |
| Net Income | -$61.2M | -$40.2M | -$6.1M |
| Op. Margin | - | -159.3% | -16.8% |
| Net Margin | - | -140.9% | -8.5% |
| Balance Sheet | |||
| Total Assets | $136.8M | $119.2M | $257.6M |
| Equity | - | $33.4M | $206.8M |
| ROE | - | -120.4% | -3.0% |
| Per Share | |||
| EPS | $-13.38 | $-6.69 | $-0.55 |
| Cash Flow | |||
| Operating CF | - | -$51.1M | -$41.1M |
| CapEx | $255K | $28K | $66K |
Source: XBRL data in Assembly Biosciences Inc (ASMB)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ASMB share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 22 | $226.2M |
| Q2 2026 | 22 | $213.8M |
| Q1 2026 | 18 | $167.7M |
| Q4 2025 | 16 | $202.4M |
| Q3 2025 | 15 | $164.1M |
| Q2 2025 | 12 | $49.7M |
| Q1 2025 | 11 | $24.9M |
| Q4 2024 | 6 | $40.5M |
- BlackRock+721.2K (+94%)
- State Street Corp+387.7K (+225%)
- Citadel Advisors LLC+283.9K (+296%)
- Millennium Management+191.3K (+64%)
- Renaissance Technologies LLC+72.6K (+184%)
- JPMorgan Chase & Co−39.0K (-84%)
- Two Sigma Investments−8.8K (-49%)
- Wells Fargo & Co−5.7K (-69%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 122 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ASMB filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 12, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Nov 12, 2026 | - | Analysis | - |
| 4 | Nov 3, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 4 | Nov 3, 2026 | - | - | - |
| 8-K | Aug 14, 2026 | - | Analysis | - |
| 8-K | Aug 13, 2026 | - | Analysis | - |
| 10-Q | Aug 13, 2026 | Jun 30, 2026 | - | |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 8-K | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | May 27, 2026 | - | - | |
| 8-K | May 26, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ASMB SEC filings: frequently asked questions
Are ASMB insiders buying or selling?
In the last 90 days, Assembly Biosciences Inc (ASMB) officers, directors and 10% owners reported no open-market purchases and 8 open-market sales worth $237,648 by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ASMB stock?
As of September 30, 2026, the largest Assembly Biosciences Inc (ASMB) holders among the 13F filers tracked by SignalX were Gilead Sciences ($116.9 million), BlackRock ($35.0 million), Vanguard Capital Management LLC ($14.2 million), State Street Corp ($13.1 million), Millennium Management ($11.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ASMB's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Assembly Biosciences Inc (ASMB) reported revenue of $72.3 million (up 153.5% from FY2024) and a net loss of $6.1 million. Diluted EPS was -$0.55. The figures come from the XBRL data in the 10-K.
What did ASMB report in its latest 8-K?
Assembly Biosciences Inc (ASMB) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for the quarter ended September 30, 2026.
What are the latest ASMB SEC filings?
Assembly Biosciences Inc (ASMB) filed its latest 10-K annual report on March 19, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on November 3, 2026.
What is ASMB's SEC CIK number?
Assembly Biosciences Inc (ASMB)'s SEC Central Index Key (CIK) is 1426800. EDGAR lists every ASMB filing under that number.
Ask anything about ASMB
The research agent reads ASMB's filings, financials, insider trades and 13F holders, then answers with sources.